2021
Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study
Meckstroth S, Wang R, Ma X, Podoltsev N. Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e551-e558. PMID: 33648884, DOI: 10.1016/j.clml.2021.01.025.Peer-Reviewed Original ResearchConceptsPatterns of careOlder patientsEnd Results-Medicare databaseJAK inhibitor eraHigh-risk patientsPopulation-based studyUse of ruxolitinibJAK inhibitor ruxolitinibUnited States FoodRuxolitinib approvalMedian ageMedian timeTreatment patternsD claimsCurrent treatmentInhibitor ruxolitinibPatientsBetter outcomesClinical experienceDrug AdministrationMedicare Part BMyelofibrosisRuxolitinibStates FoodNew drugs
2009
Clarification on the categorization of comorbidities
Wang R, Ma X. Clarification on the categorization of comorbidities. Leukemia Research 2009, 34: e74. PMID: 19783302, PMCID: PMC2815216, DOI: 10.1016/j.leukres.2009.08.036.Peer-Reviewed Original ResearchComorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes
Wang R, Gross CP, Halene S, Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leukemia Research 2009, 33: 1594-1598. PMID: 19324411, PMCID: PMC2749891, DOI: 10.1016/j.leukres.2009.02.005.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeHazard ratioComorbid conditionsMDS patientsCharlson indexMultivariate Cox proportional hazards modelPrognosis of MDSChronic obstructive pulmonary diseaseCox proportional hazards modelLarge population-based studyCongestive heart failureObstructive pulmonary diseaseRole of comorbiditiesMedian survival timePopulation-based studyProportional hazards modelMDS survivalHeart failurePulmonary diseaseIndependent determinantsShorter survivalLarge cohortSurvival timeHazards modelComorbidities